Tag

Ibrx

All articles tagged with #ibrx

markets2 months ago•16 min saved

ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA

ImmunityBio (IBRX) shares rose about 26% after the FDA outlined a potential resubmission path for ANKTIVA in BCG-unresponsive papillary non-muscle invasive bladder cancer, saying additional information is needed to support a supplemental Biologics License Application but no new clinical trials are required, a development investors view as de-risking the regulatory process and potentially enabling a broader label. Trading volume surged on Nasdaq amid the regulatory update and ongoing volatility around ANKTIVA’s commercialization prospects.

via Nasdaq|

#anktiva #bladder-cancer #fda

markets2 months ago•2 min saved

ImmunityBio's 700% Revenue Surge Spurs Hedge Fund Bets on Anktiva

ImmunityBio reported 2025 revenue of about $113 million, a 700% year-over-year increase, with Q4 revenue of $38.3 million up 431% driven by rapid scaling of lead oncology therapy Anktiva; major funds such as Citadel and Renaissance increased their holdings, signaling investors are betting on faster commercialization rather than trial risk as the stock climbs year-to-date.

via Benzinga|

#anktiva #hedge-funds #ibrx

market-news2 months ago•15 min saved

ImmunityBio's Anktiva Sparks 700% Sales Leap and Global Approvals

ImmunityBio (IBRX) stock jumped over 30% after 2025 preliminary results showed Anktiva sales up about 700% year-over-year to roughly $113 million, with Q4 2025 revenue up 431% to $38.3 million. Regulatory wins expanding Anktiva’s reach include Saudi approvals for NSCLC combinations and for bladder cancer with BCG, while Phase 2b enrollment for first-line bladder cancer is progressing. Analysts sketch a bullish picture with a Strong Buy rating and a roughly $7.33 price target, implying substantial upside potential.

via TipRanks|

#anktiva #biotech #ibrx